{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:47Z","timestamp":1786982747877,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40257-023-00762-y","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T14:02:23Z","timestamp":1678284143000},"page":"333-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Recurrent Melanoma Following Adjuvant Therapy"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-9658","authenticated-orcid":false,"given":"Nausicaa","family":"Malissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-153X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"762_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III Melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial. J Clin Oncol. 2020;38:3925\u201336.","journal-title":"J Clin Oncol"},{"key":"762_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465\u201377.","journal-title":"Lancet Oncol"},{"key":"762_CR3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet"},{"key":"762_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.","journal-title":"J Transl Med"},{"key":"762_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Kirkwood JM, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage iii melanoma. N Engl J Med. 2020;383:1139\u201348.","journal-title":"N Engl J Med"},{"key":"762_CR6","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"U Keilholz","year":"2020","unstructured":"Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435\u201348.","journal-title":"Ann Oncol"},{"key":"762_CR7","doi-asserted-by":"publisher","unstructured":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma | NEJM Evidence [Internet]. [cited 2022 Sep 20]. https:\/\/doi.org\/10.1056\/EVIDoa2200214.","DOI":"10.1056\/EVIDoa2200214"},{"key":"762_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejca.2021.09.023","volume":"158","author":"AM Eggermont","year":"2021","unstructured":"Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG\/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur J Cancer. 2021;158:156\u201368.","journal-title":"Eur J Cancer"},{"key":"762_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"762_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","volume":"31","author":"CN Owen","year":"2020","unstructured":"Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy\u2606. Ann Oncol. 2020;31:1075\u201382.","journal-title":"Ann Oncol"},{"key":"762_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","volume":"22","author":"I Pires da Silva","year":"2021","unstructured":"Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22:836\u201347.","journal-title":"Lancet Oncol"},{"key":"762_CR12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41416-020-01121-y","volume":"124","author":"P Bhave","year":"2021","unstructured":"Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br J Cancer. 2021;124:574\u201380.","journal-title":"Br J Cancer"},{"key":"762_CR13","first-page":"9535","volume":"40","author":"PA Ascierto","year":"2022","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Phase II study SECOMBIT (sequential combo immuno and target therapy study): a subgroup analysis with a longer follow-up. JCO Wolters Kluwer. 2022;40:9535\u20139535.","journal-title":"JCO. Wolters Kluwer"},{"key":"762_CR14","doi-asserted-by":"publisher","first-page":"S1408","DOI":"10.1016\/j.annonc.2022.08.040","volume":"33","author":"PA Ascierto","year":"2022","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation. Annals of Oncology Elsevier. 2022;33:S1408\u20139.","journal-title":"Annals of Oncology. Elsevier"},{"key":"762_CR15","doi-asserted-by":"publisher","unstructured":"DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial\u2014ECOG-ACRIN EA6134. J Clini Oncology. 2022. https:\/\/doi.org\/10.1200\/JCO.2021.39.36_suppl.356154cited 2022 Sep 14","DOI":"10.1200\/JCO.2021.39.36_suppl.356154"},{"key":"762_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002995","volume":"9","author":"PKH Lau","year":"2021","unstructured":"Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, et al. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). J Immunother Cancer. 2021;9: e002995.","journal-title":"J Immunother Cancer"},{"key":"762_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/pcmr.12835","volume":"33","author":"ILM Reijers","year":"2020","unstructured":"Reijers ILM, Rozeman EA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. Pigment Cell Melanoma Res. 2020;33:498\u2013506.","journal-title":"Pigment Cell Melanoma Res"},{"key":"762_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672\u201381.","journal-title":"Lancet Oncol"},{"key":"762_CR19","doi-asserted-by":"publisher","first-page":"S937","DOI":"10.1016\/j.annonc.2022.07.974","volume":"33","author":"I Marquez-Rodas","year":"2022","unstructured":"Marquez-Rodas I, Guerrero MAB, Couselo EM, Soria A, Cerezuela-Fuentes P, Mozo JLM, et al. 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801. Annals of Oncology Elsevier. 2022;33:S937\u20138.","journal-title":"Annals of Oncology. Elsevier"},{"key":"762_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"762_CR21","doi-asserted-by":"publisher","unstructured":"AWeber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023:41(3):517\u2013527. https:\/\/doi.org\/10.1200\/JCO.22.00533.","DOI":"10.1200\/JCO.22.00533"},{"key":"762_CR22","doi-asserted-by":"publisher","unstructured":"Augustin RC, Luke JJ. Induction exposure dose of ipilimumab and failure of adjuvant nivolumab plus ipilimumab in melanoma. J Clin Oncol. 2023;41(3):443-446. https:\/\/doi.org\/10.1200\/JCO.22.01770.","DOI":"10.1200\/JCO.22.01770"},{"key":"762_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2021.04.003","volume":"151","author":"JM Versluis","year":"2021","unstructured":"Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, et al. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: a multicentre retrospective analysis. Eur J Cancer. 2021;151:72\u201383.","journal-title":"Eur J Cancer"},{"key":"762_CR24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","volume":"31","author":"O Michielin","year":"2020","unstructured":"Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1449\u201361.","journal-title":"Ann Oncol"},{"key":"762_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40265-018-0945-z","volume":"78","author":"N Malissen","year":"2018","unstructured":"Malissen N, Grob J-J. Metastatic melanoma: recent therapeutic progress and future perspectives. Drugs. 2018;78:1197\u2013209.","journal-title":"Drugs"},{"key":"762_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386:24\u201334.","journal-title":"N Engl J Med"},{"key":"762_CR27","doi-asserted-by":"publisher","first-page":"v611","DOI":"10.1093\/annonc\/mdx440.011","volume":"28","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Bono P, Bhatia S, Melero I, Nyakas MS, Svane I-M, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti\u2013PD-1\/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Annals of Oncology Elsevier. 2017;28:v611\u20132.","journal-title":"Annals of Oncology. Elsevier"},{"key":"762_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","volume":"33","author":"T Inozume","year":"2010","unstructured":"Inozume T, Hanada K-I, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33:956\u201364.","journal-title":"J Immunother"},{"key":"762_CR29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang N-AAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120-11331.e17.","journal-title":"Cell"},{"key":"762_CR30","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.4049\/jimmunol.166.6.3900","volume":"166","author":"TF Gajewski","year":"2001","unstructured":"Gajewski TF, Fallarino F, Fields PE, Rivas F, Alegre ML. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001;166:3900\u20137.","journal-title":"J Immunol"},{"key":"762_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303\u201310.","journal-title":"J Exp Med"},{"key":"762_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","volume":"10","author":"N Budimir","year":"2022","unstructured":"Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell exhaustion in cancer: lessons learned from Pd-1\/Pd-l1 immune checkpoint blockade. Cancer Immunol Res. 2022;10:146\u201353.","journal-title":"Cancer Immunol Res"},{"key":"762_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD-1\/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71\u201381.","journal-title":"Cancer Treat Rev"},{"key":"762_CR34","doi-asserted-by":"publisher","first-page":"1738812","DOI":"10.1080\/2162402X.2020.1738812","volume":"9","author":"J Charles","year":"2020","unstructured":"Charles J, Chaperot L, Hannani D, Bruder Costa J, Templier I, Trabelsi S, et al. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. Oncoimmunology. 2020;9:1738812.","journal-title":"Oncoimmunology."},{"key":"762_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"762_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"762_CR37","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/cncr.30491","volume":"123","author":"EN Baruch","year":"2017","unstructured":"Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G. Adoptive T cell therapy: An overview of obstacles and opportunities. Cancer. 2017;123:2154\u201362.","journal-title":"Cancer"},{"key":"762_CR38","doi-asserted-by":"publisher","first-page":"S1406","DOI":"10.1016\/j.annonc.2022.08.036","volume":"33","author":"JBAG Haanen","year":"2022","unstructured":"Haanen JBAG, Rohaan M, Borch TH, van den Berg JH, Met \u00d6, Foppen MG, et al. LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase III trial. Ann Oncol. 2022;33:S1406.","journal-title":"Ann Oncol"},{"key":"762_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T Cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109-1119.e10.","journal-title":"Cell"},{"key":"762_CR40","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","volume":"32","author":"A Ribas","year":"2021","unstructured":"Ribas A, Chesney J, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL). Ann Oncol. 2021;32:S868\u20139.","journal-title":"Ann Oncol"},{"key":"762_CR41","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1200\/JCO.20.03246","volume":"39","author":"RHI Andtbacka","year":"2021","unstructured":"Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, et al. Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol. 2021;39:3829\u201338.","journal-title":"J Clin Oncol"},{"key":"762_CR42","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/2159-8290.CD-20-1546","volume":"11","author":"C Haymaker","year":"2021","unstructured":"Haymaker C, Johnson DH, Murthy R, Bentebibel S-E, Uemura MI, Hudgens CW, et al. Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021;11:1996\u20132013.","journal-title":"Cancer Discov"},{"key":"762_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"762_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14: e0212513.","journal-title":"PLoS ONE"},{"key":"762_CR45","doi-asserted-by":"publisher","first-page":"S1173","DOI":"10.1016\/j.annonc.2020.08.2274","volume":"31","author":"AMA Fernandez","year":"2020","unstructured":"Fernandez AMA, O\u2019Day SJ, de la Merino LC, Petrella T, Jamal R, Ny L, et al. LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Ann Oncol. 2020;31:S1173.","journal-title":"Ann Oncol"},{"key":"762_CR46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"key":"762_CR47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"762_CR48","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 2020;10:1140\u201357.","journal-title":"Cancer Discov"},{"key":"762_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell. 2019;35:238-255.e6.","journal-title":"Cancer Cell"},{"key":"762_CR50","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"762_CR51","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602\u20139.","journal-title":"Science"},{"key":"762_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin J-M, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595\u2013602.","journal-title":"Science"},{"key":"762_CR53","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, V\u00e9tizou M, Daill\u00e8re R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44:1255\u201369.","journal-title":"Immunity"},{"key":"762_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21:358\u201372.","journal-title":"Lancet Oncol"},{"key":"762_CR55","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1200\/JCO.2016.34.15_suppl.9502","volume":"34","author":"K Flaherty","year":"2016","unstructured":"Flaherty K, Davies MA, Grob JJ, Long GV, Nathan PD, Ribas A, et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma. JCO. 2016;34:9502\u20139502.","journal-title":"JCO"},{"key":"762_CR56","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","volume":"25","author":"M Offin","year":"2019","unstructured":"Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, et al. tumor mutation burden and efficacy of eGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res. 2019;25:1063\u20139.","journal-title":"Clin Cancer Res"},{"key":"762_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1468955","volume":"7","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition. Oncoimmunology. 2018;7: e1468955.","journal-title":"Oncoimmunology."},{"key":"762_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40271-021-00507-1","volume":"14","author":"A Livingstone","year":"2021","unstructured":"Livingstone A, Milne D, Dempsey K, Muscat DM, Menzies AM, Howard K, et al. Should I have adjuvant immunotherapy? An interview study among adults with resected stage 3 melanoma and their partners. Patient. 2021;14:635\u201347.","journal-title":"Patient"},{"key":"762_CR59","doi-asserted-by":"publisher","first-page":"S1408","DOI":"10.1016\/j.annonc.2022.08.039","volume":"33","author":"S Patel","year":"2022","unstructured":"Patel S, Othus M, Prieto V, Lowe M, Buchbinder E, Chen Y, et al. LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801). Ann Oncol. 2022;33:S1408.","journal-title":"Ann Oncol"},{"key":"762_CR60","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20:e378\u201389.","journal-title":"Lancet Oncol"},{"key":"762_CR61","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178\u201388.","journal-title":"Nat Med"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00762-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T01:15:09Z","timestamp":1684372509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00762-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"31 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NM declares having received advisory fees from Bristol Myers Squibb and Novartis, payment for lectures and meeting invitations from Novartis, Bristol Myers Squibb, Sanofi and MSD. J-JG reports advisory\/consultancy roles with Bristol Myers Squibb, MSD, Novartis, Roche, Philogen, Pierre Fabre, Sanofi, Amgen, Merck and Pfizer; and travel accommodations and\/or expenses from BMS and Pierre Fabre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"NM wrote the original draft and J-JG supervised, reviewed and edited the published work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}